HuGE Literature Finder
Records
1
-
3
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investigational new drugs 2019 Nov . Bendell Johanna C, Bischoff Helge G, Hwang Jimmy, Reinhardt Hans Christian, Zander Thomas, Wang Xuejing, Hynes Scott, Pitou Celine, Campbell Robert, Iversen Philip, Farrington Daphne L, Bell-McGuinn Katherine, Thomas Micha |
Effect of RAS status on anti-EGFR monoclonal antibodies + 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis. Meta gene 2016 Sep 9 110-9. Zhou Mingyi, Yu Ping, Hou Kezuo, Fu Lingyu, Chen Ying, Qu Jinglei, Qu Xiujuan, Liu Yunpeng, Zhang Jingdo |
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 16, 2022
- Content source: